Additionally, high UCP2 expression is known to favor a highly glycolytic metabolic profile, therefore suggesting that more aggressive gliomas may have an increased dependency on glycolysis and may be more susceptible to anti-glycolytic treatments. Here, UCP2 is linked to glioma.